Mikko Mäkinen and Nomad Invest Oy have taken a position in the company. Also, a certain former javelin thrower has appeared on the list. Here are all the new shareholders on the largest shareholders list:
Quite a few, including Cor, are taking a positive view of the company at this valuation level. In practice, Perk is selling for their own reasons while others are scooping up shares, presumably without insider information. Some are certainly looking for shorter-term returns, but nevertheless.
There are so many entirely new owners with significantly sized positions that the broker has likely been making some calls, since there were a few million shares up for grabs; in other words, the setup required a bit of preparation.
A speculative thought, but a thought nonetheless.
And the OTC side went silent as well—no trades yesterday.
Yesterday, there was a volume of 2.1 million. Apparently, it is possible to execute block trades on the OTC market without them appearing as individual trades in that data.
Well, that would make 6.5 million shares traded on the OTC already. I wonder if the operation is finished yet, whatever it may be.
Who bought the block?
Highlights from the article published by the University of Eastern Finland on May 28:
"Demonstrating the effectiveness of preventive healthcare has traditionally required long follow-up studies spanning several years because diseases develop slowly. NMR metabolomics (NMR-metabolomiikka) changes this setup, as a single blood sample can provide separate risk assessments for several chronic diseases. This allows us to evaluate how interventions change the risk of each disease within a timeframe of just months, states the project leader, Professor Janne Martikainen from the university’s School of Pharmacy.
The results can later be verified through long-term follow-up in national health registries once actual incidences of illness begin to appear in the records.
Why is such research important?
Wellbeing services counties (hyvinvointialueet) are looking for ways to shift the focus of healthcare from reactive disease treatment toward proactive health promotion. This transition requires reliable information on which operating models produce the best health benefits with the available resources. The research linked to the ‘Hyvinvointilahja’ project produces this type of information pragmatically, in a real-world service environment—not just under experimental conditions.
The project results serve both Eloisa’s own decision-making regarding whether to establish the model as a permanent part of operations, and the considerations of other wellbeing services counties and national policymakers regarding the broader implementation of similar models."
Here is a new company report on Nightingale from Antti & Antti at Inderes following the latest news
During the beginning of the year, Nightingale has announced three new projects or partnerships. In our assessment, these new ventures are pilot-type projects, and their potential commercial significance will only become clear in the medium term. As no significant new information regarding major new projects or the progress of ongoing commercialization has been received during the early part of the year, we are revising our forecasts for the coming years and, accordingly, lowering our target price to EUR 1.4 (prev. EUR 1.7). The share price has declined very sharply since the financial statements report, which has improved the risk/reward ratio. Consequently, we are upgrading our recommendation to Buy (prev. Accumulate).
An interesting justification for the target price, considering that when deals are announced, they are announced, and they cannot be predicted in advance. Once a good deal for the clinical side is pushed through the pipeline, it will validate the demand side quite nicely in one fell swoop.
But targets have to follow the share price level, that’s clear, hence the downward adjustment.
I’ll argue against that a bit: an analyst must assume these deals and the progress of projects behind their forecasts if they expect revenue growth. What else would the assumption of growth be built on?
Then, the news flow provides one clear data point on the validity of these assumptions. Regarding Nightingale’s healthcare partnerships, it’s about recurring/repeating revenue, and the news flow perhaps says more about the growth of this revenue. On the research side, they sell projects, and here the news flow gives a sense of whether the revenue level can be maintained at all, or in the best case, increased. Not all information is evident from public records, but for lack of better data, that’s what we have to play with here.
In addition to that target price of €1.4, Antti’s analysis mentioned a wider range of €0.5–€5; in that sense, the difficulty of determining the valuation for this type of stock was acknowledged.
Antti and Miksu discussed how things are going with Nightingale
Topics:
(00:00) Introduction
(00:13) Share price has tanked
(02:14) Development in recent years
(04:18) Is there demand for the service?
(08:35) Research projects and partnerships
(10:24) Buy recommendation, despite plenty of uncertainties
